Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.62 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.49 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.42 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.42 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.63 |
| ▸ | CA3 | P07451 | 2/20 | 0.62 |
| ▸ | CA5A | P35218 | 2/20 | 0.62 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA4 | P22748 | 1/20 | 0.62 |
| ▸ | CA6 | P23280 | 1/20 | 0.62 |
| ▸ | CA7 | P43166 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29241679 | 0.98 | SMN1; SMN2 (0.75) | MEN1KMT2ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL5367616 | 0.98 | MEN1 (0.79) | MEN1KMT2ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL19781069 | 0.98 | MEN1 (0.79) | MEN1KMT2ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL6490885 | 0.96 | ALDH1A1 (0.78) | MEN1KMT2ASMN1; SMN2ALDH1A1POLB | |
| Trifluoroacetic Acid SCHEMBL30387588 | 0.92 | MEN1 (0.70) | MEN1KMT2ASMN1; SMN2ALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL29241548 | 0.92 | SMN1; SMN2 (0.71) | MEN1KMT2ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL3149189 | 0.90 | ALDH1A1 (0.74) | MEN1KMT2ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL11981741 | 0.89 | CA5A (0.81) | MEN1KMT2ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL29982917 | 0.87 | MEN1 (1.00) | MEN1KMT2ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL27889238 | 0.85 | ALDH1A1 (1.00) | MEN1KMT2ASMN1; SMN2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236635-A1 | METHODS OF SEQUENCING USING NUCLEOTIDES WITH 3' ACETAL BLOCKING GROUP | ILLUMINA CAMBRIDGE LIMITED (GB) | 2025-07-24 | — | — | US | disclosed |
| US-12286453-B2 | Methods of sequencing using nucleotides with 3′ acetal blocking group | ILLUMINA CAMBRIDGE LIMITED (GB) | 2025-04-29 | — | — | US | disclosed |
| US-20240209015-A1 | METHODS OF SEQUENCING USING 3' BLOCKED NUCLEOTIDES | ILLUMINA, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240132532-A1 | METHODS OF SEQUENCING USING NUCLEOTIDES WITH 3' ACETAL BLOCKING GROUP | ILLUMINA CAMBRIDGE LIMITED (GB) | 2024-04-25 | — | — | US | disclosed |
| US-11787831-B2 | Nucleosides and nucleotides with 3′ acetal blocking group | ILLUMINA CAMBRIDGE LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| EP-4168421-A1 | NUCLEOSIDES AND NUCLEOTIDES WITH 3' ACETAL BLOCKING GROUP | Illumina Cambridge Limited (GB) | 2023-04-26 | — | — | EP | disclosed |
| CN-115867560-A | Nucleosides and nucleotides having 3' acetal capping groups | 伊鲁米纳剑桥有限公司 | 2023-03-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236635-A1 | METHODS OF SEQUENCING USING NUCLEOTIDES WITH 3' ACETAL BLOCKING GROUP | RNGTT, NSUN2, NT5C3B | CA2 3764/4885HDAC6 2769/4885MAOA 1606/4885 |
| US-20240132532-A1 | METHODS OF SEQUENCING USING NUCLEOTIDES WITH 3' ACETAL BLOCKING GROUP | RNGTT, NSUN2, NT5C3B | CA2 3764/4885HDAC6 2769/4885MAOA 1606/4885 |
| US-11787831-B2 | Nucleosides and nucleotides with 3′ acetal blocking group | DUT, ADAR, NT5C3B | CA2 4031/4885HDAC6 1406/4885MAOA 2295/4885 |
| US-20240209015-A1 | METHODS OF SEQUENCING USING 3' BLOCKED NUCLEOTIDES | RNGTT, NT5C3B, NSUN2 | CA2 4644/4885HDAC6 2560/4885MAOA 3267/4885 |
| US-12286453-B2 | Methods of sequencing using nucleotides with 3′ acetal blocking group | RNGTT, NSUN2, NT5C3B | CA2 3830/4885HDAC6 2687/4885MAOA 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.